Morgan Stanley analyst Michael Ulz downgraded Third Harmonic Bio to Equal Weight from Overweight with a price target of $5, down from $34.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on THRD:
- Third Harmonic Tanks After Axing Clinical Trial
- Third Harmonic Bio discontinues Phase 1b study of THB001
- Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference
- Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update
